Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataDextromethorphan and quinidine combination for heroin detoxification.Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affectPseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.Addressing phenoconversion: the Achilles' heel of personalized medicine.Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan.Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidinePharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditionsDextromethorphan/quinidine: a novel dextromethorphan product for the treatment of emotional lability.A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.Pharmacogenetics of analgesics: toward the individualization of prescription.Dextromethorphan/quinidine: in pseudobulbar affect.Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations.Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.Advancements in the treatment of agitation in Alzheimer's disease.AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer.Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents.Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome.Dextromethorphan abuse leading to assault, suicide, or homicide.Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.Dextromethorphan poisoning: an evidence-based consensus guideline for out-of-hospital management.Treatment of Pseudobulbar Affect With Fluoxetine and Dextromethorphan in a Woman With Multiple Sclerosis.
P2860
Q27009128-A578EB94-0228-4B05-BC00-E2BE3126C097Q30418597-C382924B-E221-4726-9A4F-29A4B780113AQ30634431-9FBF3FDC-BF94-42ED-83ED-451D79ED7ADEQ33838839-291EBBBF-CD05-488E-A215-A9C18851D62AQ34026748-0D672F8F-9FE7-4AE8-B35D-264D5EAC01E8Q35023701-5C9F3AB0-3567-4FC2-9084-D97C8FA23BD6Q35108500-CB62341C-4251-430F-96ED-DCBA56B3536AQ36100597-0670343C-F4C9-4A28-B056-47DD59D9EBEDQ36365500-88DA7190-B036-4A85-8AD2-2A72312EE8D2Q36551001-AAECD997-5194-4FC0-868F-D2822DE8CEF6Q36675422-B7162682-2957-46EC-872D-F08310017815Q37021521-6338AA73-475A-44FD-9C0F-25A7F121E8E3Q37205954-B3B5FD2C-F873-4556-9E9D-83501327AABDQ37863094-82F35C46-E9F6-47E7-A6F3-5D0D58FAF857Q38099049-E259DF9E-25B3-4709-B23E-93806805C840Q38270903-5665F83A-6E2F-4044-8A30-B12E88CCF8B8Q38543238-AD3B6BD2-7D03-406E-A31B-BAA6022A39FFQ38544531-51908194-EC63-48F0-9B78-85179607122AQ39034436-90485B6F-364F-41EA-8515-15CE43F969F3Q39353969-23321C17-E234-46A7-8B91-6C99194503BEQ41009555-410A97BB-3095-4C6C-AEAB-4F4678A6D938Q42672227-09B304BC-27A0-4E64-B5E6-E225D10EA26BQ46280394-2CC04E2C-C279-40B8-8314-EA5048F34934Q47924035-BC049553-ED09-4C8F-82D5-B966FDE3D367Q47930548-4EC681A7-A19A-4AE6-AEF0-E312025E2BA1Q48691370-7870AE9B-07A8-44DC-A3EF-60ACD968F63CQ50707361-23CE510A-EE88-4AB8-AE5F-73BF263030DEQ51906189-EB3E14C2-9352-4EAA-9B7F-9406F946CA35Q53731683-06EA2ED6-4F68-454C-B600-C8515A26250D
P2860
Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacokinetics of dextrometh ...... tensive and poor metabolizers.
@en
Pharmacokinetics of dextrometh ...... tensive and poor metabolizers.
@nl
type
label
Pharmacokinetics of dextrometh ...... tensive and poor metabolizers.
@en
Pharmacokinetics of dextrometh ...... tensive and poor metabolizers.
@nl
prefLabel
Pharmacokinetics of dextrometh ...... tensive and poor metabolizers.
@en
Pharmacokinetics of dextrometh ...... tensive and poor metabolizers.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics of dextrometh ...... tensive and poor metabolizers.
@en
P2093
Gerald J Yakatan
James E Berg
Laura E Pope
M H Khalil
Mark Stiles
P2860
P304
P356
10.1177/0091270004269521
P577
2004-10-01T00:00:00Z